Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3252W HIGH $4.23
Volume
6.24 M
Value Traded
7.70 M
Short % Float
25.76%
Days to Cover
6.3
-16.15%Week
-32.5%1 Month
-50.55%3 Month
-52.8%6 Month
-67.5%5 Year
-59.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
228.89 M
EPS (TTM)
-1.07
P/E Ratio
-
Ent. Value
3.79 M
Total Shares
169.55 M
Float Shares
149.89 M
Insiders
11.59%
Institutions
82.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CABA Catalyst Timeline
Dated clinical, regulatory and corporate events for Cabaletta Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cabaletta Bio, Inc.
517Total events
16Upcoming
79Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Inducement stock options granted to four newly hired non-executive employees
▲RMATrese-celDesignation
rese-cel granted RMAT designation for gMG
generalized myasthenia gravissource ↗
◆Topline Readoutrese-celClinical Data
PC-free rese-cel data including longer-term follow up at the initial dose in 2H26
pemphigus vulgarissource ↗
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
◆Poster Presentationrese-celPresentation
Translational data from across Phase 1/2 cohorts presented at EULAR 2026
autoimmune diseasessource ↗
◆Oral Presentationrese-celPresentation
Longer-term follow-up from Phase 1/2 DM and ASyS cohorts presented at EULAR 2026
dermatomyositis, antisynthetase syndromesource ↗
◆Topline Readoutrese-celClinical Data
Initial data at lowest rese-cel dose from RESET-SLE expected at EULAR 2026
systemic lupus erythematosussource ↗
◆Oral Presentationrese-celPresentation
EULAR 2026 Congress presentations of rese-cel data across myositis, lupus, systemic sclerosis
autoimmune diseasessource ↗
◆Timing Guidancerese-celPresentation
Potential update on registrational trial design for RESET-MG expected
myasthenia gravissource ↗
◆Timing GuidancePresentation
Second pivotal indication for advancement to be announced after EULAR 2026
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference
◆Poster Presentationrese-celPresentation
End-to-end fully automated CAR T manufacturing using the Cellares Cell Shuttle Platform: Initial translational data from autoimmune patients treated in RESET trials with rese-cel
autoimmune diseasessource ↗
▲Oral Presentationrese-celPresentation
Initial clinical experience with Cellares-manufactured rese-cel presented at ASGCT 2026
pemphigus vulgarissource ↗
▲Enrollment Updaterese-celTrial
Registrational RESET-Myositis trial enrollment progressing well
dermatomyositis, antisynthetase syndromesource ↗
◆Oral Presentationrese-celPresentation
Single-cell profiling of PBMC subsets following rese-cel treatment across the RESET-Myositis, RESET-SSc, and RESET-SLE trials Phase 1/2 Cohorts
myositis, systemic sclerosis, systemic lupus erythematosussource ↗
◆Oral Presentationrese-celPresentation
Product quality for Resecabtagene autoleucel between healthy donors and autoimmune patients in the RESET clinical trial program starting material is consistent and platform agnostic
autoimmune diseasessource ↗
▼Equity OfferingCorporate
Pricing of $150 million underwritten offering of 51,725,000 shares at $2.90 per share
◆Oral Presentationrese-celPresentation
Initial translational data from first two patients dosed with rese-cel manufactured by Cellares at ASGCT conference
autoimmune diseasessource ↗
▲Management ChangeCorporate
Appointment of Francisco Ramirez-Valle to Scientific Advisory Board
▲Partnership / Licenserese-celCorporate
10-year commercial supply agreement with Cellares for automated manufacture of rese-cel
autoimmune diseasessource ↗
▲First Patient Dosedrese-celTrial
First patients dosed with rese-cel manufactured on Cell Shuttle
autoimmune diseasessource ↗
▲IND Clearancerese-celIND
FDA clearance of IND amendment for clinical manufacturing using Cell Shuttle
autoimmune diseasessource ↗
◆Oral Presentationrese-celPresentation
Oral presentation of complete Phase 1/2 data from RESET-MG at AAN Annual Meeting
myasthenia gravissource ↗
▲First Patient Dosedrese-celTrial
Initial patients dosed using automated, scalable manufacturing of rese-cel
pemphigus vulgarissource ↗
▲First Patient Dosedrese-celTrial
First JDM patient dosed with rese-cel
juvenile dermatomyositissource ↗
▲First Patient Dosedrese-celTrial
First two patients dosed with rese-cel manufactured on Cell Shuttle platform
autoimmune diseasessource ↗
▲First Patient Dosedrese-celTrial
First patients dosed with Rese-cel manufactured on Cellares' Automated Cell Shuttle Platform
◆Additional Datarese-celClinical Data
Longer-term clinical data from patients receiving Cellares-manufactured rese-cel expected in 2H26
autoimmune diseasessource ↗
◆Topline Readoutrese-celClinical Data
Initial PC-free data from lowest dose RESET-SLE cohort expected
systemic lupus erythematosussource ↗
◆Timing Guidancerese-celPresentation
Update on registrational alignment for RESET-MG
myasthenia gravissource ↗
▲Full Resultsrese-celClinical Data
Complete Phase 1/2 cohort data from RESET-MG presented at AAN Annual Meeting
myasthenia gravissource ↗
▲Partnership / Licenserese-celCorporate
10-year commercial supply agreement with Cellares announced
▲Oral Presentationrese-celPresentation
Complete RESET-MG Phase 1/2 data shared at AAN Annual Meeting April 2026
generalized myasthenia gravissource ↗
◆Oral PresentationPresentation
Participation in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
▲IND Clearancerese-celIND
IND amendment cleared for Cellares manufacturing
autoimmune diseasessource ↗
▲FDA Feedback Receivedrese-celFDA Meeting
FDA alignment on registrational cohort designs in SLE and LN
systemic lupus erythematosus and lupus nephritissource ↗
▲Enrollment Updaterese-celTrial
Registrational cohort expanded to 17 patients (14 DM, 3 ASyS)
dermatomyositis and antisynthetase syndromesource ↗
▲Trial Initiationrese-celTrial
No preconditioning dose-escalation cohort added in RESET-SLE
systemic lupus erythematosussource ↗
▲IND Clearancerese-celIND
FDA clearance of IND amendment to use Cell Shuttle platform for clinical manufacturing of rese-cel
autoimmune diseasessource ↗
◆Enrollment Completerese-celTrial
Complete phase 1/2 data expected in systemic sclerosis in 1H26
systemic sclerosissource ↗
◆Topline Readoutrese-celClinical Data
Complete phase 1/2 data expected in systemic sclerosis in 1H26
systemic sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How CABA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-13 | rese-cel (resecabtagene autoleucel) | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 46%
Micro Cap(rank 303 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CABA-201 Monoclonal antibodyNCT06154252 | Idiopathic Inflammatory Myopathy | Phase 2 | RECRUITING | 74 | Jul 1, 2028 | ||||||
| CABA-201 Monoclonal antibodyNCT06328777 | Systemic Sclerosis | Phase 2 | RECRUITING | 37 | Jul 1, 2029 | ||||||
| CABA-201 Monoclonal antibodyNCT06121297 | Systemic Lupus Erythematosus | Phase 1 | RECRUITING | 28 | Dec 1, 2029 | ||||||
| CABA-201 Monoclonal antibodyNCT06359041 | Generalized Myasthenia Gravis (gMG) | Phase 1 | RECRUITING | 24 | Sep 1, 2029 | ||||||
| DSG3-CAART Monoclonal antibodyNCT04422912 | Pemphigus Vulgaris | Phase 1 | RECRUITING | 40 | Jan 1, 2029 | ||||||
| MuSK-CAART Monoclonal antibodyCompletedNCT05451212 | MuSK Myasthenia Gravis | Phase 1 | COMPLETED | 7 | Jul 24, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every CABA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rese-cel Fast TrackRMATOrphan | dermatomyositis | Phase 1/2 | 2026-06-03 | 83% of dermatomyositis patients achieved the primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years.Read More | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 CongressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chang David J.Officer (Chief Medical Officer) | Buy | 8,800 8,800 held | $2.26 | 01/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CABA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 3.2 % (39.1 %) | 53.62 M | 17.24 M | 78.17% ( 7.56 M) |
CABA Institutional Ownership Trends
CABA Short Interest
Shares sold short, counted twice a month.
25.76%
Short % of Float
of tradable shares sold short
38.6M
Shares Sold Short
+15.9% vs prior count
6.3 High
Days to Cover
trading days of normal volume to buy every short share back
6.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CABA ranks across every disease it competes in
Competitive Position is a premium feature
See how CABA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCABA News
CABACabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cabaletta Bio has announced the grant of inducement equity awards to four newly hired non-executive employees, as part of their onboarding process. The awards include non-qualified stock options totaling 385,000 shares, with exercise prices based on recent closing stock prices. These options will vest over four years, supporting the company's growth in developing targeted cell therapies for autoimmune diseases.
Read more →CABA▲ +6.1%on this news
Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio, a late-stage clinical biotechnology company, has announced its participation in several upcoming investor conferences. These include the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. The events will feature meetings and webcasted fireside chats, showcasing the company's advancements in targeted cell therapies for autoimmune diseases.
Read more →CABACabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio reported its second quarter 2026 financial results and outlined key developments in its clinical programs. The company anticipates reporting registrational data for rese-cel in mid-2027, aiming for a BLA submission in the second half of 2027. Recent operational highlights include expanding outpatient dosing options and partnerships for manufacturing. The company is also preparing for new registrational studies in systemic sclerosis-associated interstitial lung disease.
Read more →CABACabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Cabaletta Bio announced promising new data on rese-cel, showing that 83% of dermatomyositis patients achieved the primary endpoint in the Phase 1/2 RESET-Myositis study. The company also reported early positive findings in lupus and plans to initiate a registrational study for systemic sclerosis. The data were presented at the EULAR 2026 Congress, highlighting the potential of rese-cel in treating multiple autoimmune diseases.
Read more →CABACabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio has presented new clinical and translational data for its investigational therapy, rese-cel, at the ASGCT 2026 Annual Meeting. The data highlights a 50% compelling drug-free response rate among refractory patients after receiving the lowest dose of rese-cel without preconditioning. The automated manufacturing process via the Cellares Cell Shuttle has shown promise in supporting scalability and reliability in production. This advancement could significantly enhance access to treatment for patients suffering from autoimmune diseases.
Read more →CABACabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio has announced its first quarter 2026 financial results alongside a significant update on its investigational therapy, rese-cel. The company reported promising initial data from the RESET-PV study, presenting potential drug-free clinical responses without preconditioning. The pivotal RESET-Myositis trial is advancing towards a Biologics License Application submission planned for next year. Additionally, Cabaletta closed a $150 million financing deal, suggesting robust momentum as it enters critical phases of development and commercialization.
Read more →CABA▲ +30.3%on this news· ran to +41% by day 1
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Cabaletta Bio has announced the pricing of an underwritten offering of 51,725,000 shares of common stock, expected to generate approximately $150 million. The offering is set to close on or about May 5, 2026, pending customary closing conditions. The financing has drawn interest from several prominent investors, including Bain Capital Life Sciences and Eli Lilly.
Read more →CABACabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Cabaletta Bio and Cellares have announced a 10-year commercial supply agreement for rese-cel, which aims to provide scalable and cost-effective production of this investigational CAR T cell therapy for autoimmune diseases. The partnership leverages Cellares' automated manufacturing platforms, enabling the production of thousands of batches annually. Initial patient data will be shared at the ASGCT conference in May 2026, supporting the planned BLA submission for myositis.
Read more →CABACellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cellares has signed a 10-year commercial supply agreement with Cabaletta Bio for the automated manufacture of rese-cel, a CAR T cell therapy for autoimmune diseases. This collaboration aims to meet the growing global demand for rese-cel, following successful initial patient dosing. The automated manufacturing process is designed to enhance scalability and cost-efficiency, supporting broader patient access.
Read more →CABACabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Cabaletta Bio, Inc. will present multiple studies on its investigational CAR T therapy, rese-cel, at the ASGCT 2026 Annual Meeting. The presentations will cover clinical data from the RESET-PV trial and initial results from automated manufacturing processes. These developments aim to improve treatment for autoimmune diseases, showcasing the company's commitment to advancing cell therapy.
Read more →CABADisclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer
Cabaletta Bio, Inc. has published a presentation outlining their business operations, focusing on the development of rese-cel for autoimmune diseases. The document highlights ongoing clinical trials and the company's plans for future growth and partnerships. However, it also acknowledges various risks and uncertainties that could affect the success of their product candidates and overall strategy. The company emphasizes the importance of regulatory approvals and patient enrollment in the success of its development programs.
Read more →CABAFirst Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Cabaletta Bio has successfully dosed the first patients with its Rese-cel product, which is manufactured using Cellares' Automated Cell Shuttle™ platform. This milestone marks a significant advancement in the clinical development of Rese-cel, showcasing the potential of automated cell manufacturing technology. The collaboration aims to improve the efficiency and scalability of cell therapy production.
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio reported its financial results for Q4 and full year 2025, highlighting progress in its rese-cel program for autoimmune diseases. The company is on track for a BLA submission in 2027 and is advancing innovative manufacturing processes. Upcoming clinical data is anticipated to support regulatory discussions, while the company continues to manage increased R&D expenses.
Read more →CABA▲ +13.4%on this news
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio, Inc. will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company focuses on developing targeted cell therapies for autoimmune diseases. A live webcast of the presentation will be available, with replays for 30 days. This event highlights the company's ongoing commitment to innovation in the biotech field.
Read more →CABA▼ -7.2%on this news
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cabaletta Bio, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company is focused on developing curative targeted cell therapies for autoimmune diseases, with its lead investigational therapy, rese-cel, currently evaluated in the RESET clinical program. A live webcast of the presentation will be available on their website.
Read more →CABA▲ +5.2%on this news
Cabaletta Bio Announces 2026 Strategic Priorities
Cabaletta Bio has outlined its strategic priorities for 2026, focusing on advancing the development and commercialization of its investigational CAR T cell therapy, rese-cel, for autoimmune diseases. The company is actively enrolling in a pivotal myositis trial, aiming for a BLA submission in 2027, with a 17-patient cohort designed to evaluate treatment efficacy. Additionally, the FDA has granted clearance for the automated manufacturing of rese-cel, which could improve scalability and reduce costs. Important clinical data is anticipated in 2026, which could inform the future direction of their product's development and regulatory strategies.
Read more →CABACabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio reported third quarter 2025 financial results and provided a business update on its investigational therapy rese-cel. The company plans to submit a Biologics License Application for myositis in 2027 based on a 14-patient registrational cohort. R&D expenses reached $39.8 million for the quarter ended September 30, 2025.
Read more →CABA▼ -10.3%on this news
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Cabaletta Bio, a clinical-stage biotechnology company, has announced its participation in upcoming investor conferences in November and December. The company is dedicated to developing curative targeted cell therapies for autoimmune diseases, with its lead investigational therapy, rese-cel, currently evaluated in the RESET clinical program. Webcasted fireside chats will be accessible on their website.
Read more →CABA▼ -8.8%on this news
Corporate Presentation October 2025 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the prese
Cabaletta Bio has prepared a corporate presentation outlining its strategic plans and forward-looking statements regarding its autoimmune-focused pipeline, particularly the development of its drug candidate, rese-cel. The presentation highlights ongoing clinical trials, including RESET-Myositis, RESET-SLE, and other trials aimed at demonstrating the drug's safety and efficacy. However, the company acknowledges various risks and uncertainties that may impact the success and timelines of these trials, including enrollment rates and potential regulatory challenges.
Read more →CABA▲ +13%on this newsshared move
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio presented encouraging clinical data for its investigational therapy rese-cel at ACR Convergence 2025. Key findings include significant improvements in myositis and systemic sclerosis patients, with plans to initiate a registrational trial for myositis. The RESET-SLE trial is also expanding to include a cohort without preconditioning, aiming for simpler treatment options for lupus patients.
Read more →About Cabaletta Bio, Inc.
Headquarters2929 ARCH STREET, PHILADELPHIA, PA, 19104
BIOPHARMAWATCH ELITE PLUS
Trade the next CABA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime